Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases

Authors: Keren Masha Rabinowitz, Michal Navon, Hadar Edelman-Klapper, Eran Zittan, Ariella Bar-Gil Shitrit, Idan Goren, Irit Avni-Biron, Jacob E. Ollech, Lev Lichtenstein, Hagar Banai-Eran, Henit Yanai, Yifat Snir, Maor H. Pauker, Adi Friedenberg, Adva Levy-Barda, Arie Segal, Yelena Broitman, Eran Maoz, Baruch Ovadia, Maya Aharoni Golan, Eyal Shachar, Shomron Ben-Horin, Nitsan Maharshak, Michal Mor, Haim Ben Zvi, Rami Eliakim, Revital Barkan, Tali Sharar-Fischler, Sophy Goren, Noy Krugliak, Edward Pichinuk, Michael Mor, Michal Werbner, Joel Alter, Hanan Abu-Taha, Kawsar Kaboub, Moshe Dessau, Meital Gal-Tanamy, Dani Cohen, Natalia T. Freund, Iris Dotan, on behalf of the Responses to COVID-19 Vaccine Israeli IBD Group

Source: Vaccines, Vol 10, Iss 8, p 1186 (2022)

Subject Terms: COVID-19, vaccine, mRNA-BNT162b2, anti-SARS-CoV-2 antibodies, serologic response longevity, circulating B cells, Medicine

File Description: electronic resource

Relation: https://www.mdpi.com/2076-393X/10/8/1186; https://doaj.org/toc/2076-393X

Access URL: https://doaj.org/article/002599bbb4e74664a74f8cb9e8c3051d